Genetically-Engineered TIL Therapies
We are developing a novel class of genetically-engineered TIL therapies using our Co-Stimulatory Antigen Receptor, or CoStAR, platform.
CoStAR-TIL
| Candidate | Indication | Discovery | IND-Enabling | Phase 1 | Phase 2/3 |
|---|---|---|---|---|---|
| ITIL-306 | NSCLC, Ovarian, RCC | ||||
| Multiple | Undisclosed | ||||
NSCLC: non-small cell lung cancer; RCC: renal cell carcinoma;